<?xml version="1.0" ?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.3 20210610//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">elife</journal-id>
<journal-id journal-id-type="publisher-id">eLife</journal-id>
<journal-title-group>
<journal-title>eLife</journal-title>
</journal-title-group>
<issn publication-format="electronic" pub-type="epub">2050-084X</issn>
<publisher>
<publisher-name>eLife Sciences Publications, Ltd</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">103559</article-id>
<article-id pub-id-type="doi">10.7554/eLife.103559</article-id>
<article-id pub-id-type="doi" specific-use="version">10.7554/eLife.103559.1</article-id>
<article-version-alternatives>
<article-version article-version-type="publication-state">reviewed preprint</article-version>
<article-version article-version-type="preprint-version">1.1</article-version>
</article-version-alternatives>
<article-categories><subj-group subj-group-type="heading">
<subject>Medicine</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Gamma Knife Stereotactic radiotherapy combined with tislelizumab as later-line therapy in pMMR/MSS/MSI-L metastatic colorectal cancer: A Phase II Trial Analysis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Zhang</surname>
<given-names>Yiran</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="author-notes" rid="n1">*</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0009-0002-8853-6151</contrib-id>
<name>
<surname>Guan</surname>
<given-names>Hanyang</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="author-notes" rid="n1">*</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Liu</surname>
<given-names>Shijin</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="author-notes" rid="n1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Haoquan</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bian</surname>
<given-names>Zili</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>He</surname>
<given-names>Jiashuai</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhao</surname>
<given-names>Zhan</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Qiu</surname>
<given-names>Shenghui</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mo</surname>
<given-names>Tianmu</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Xiangwei</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Zuyang</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ding</surname>
<given-names>Hui</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhao</surname>
<given-names>Xiaoxu</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Wang</surname>
<given-names>Liang</given-names>
</name>
<xref ref-type="aff" rid="a3">3</xref>
<email>wangliang@jnu.edu.cn</email>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Pan</surname>
<given-names>Yunlong</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a4">4</xref>
<email>tpanyl@jnu.edu.cn</email>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3741-3397</contrib-id>
<name>
<surname>Pan</surname>
<given-names>Jinghua</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<email>huajanve@foxmail.com</email>
</contrib>
<aff id="a1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05d5vvz89</institution-id><institution>Department of General Surgery, The First Affiliated Hospital of Jinan University</institution></institution-wrap>, <city>Guangzhou</city>, <country>China</country></aff>
<aff id="a2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05d5vvz89</institution-id><institution>Department of Body Gamma Knife, The First Affiliated Hospital of Jinan University</institution></institution-wrap>, <city>Guangzhou</city>, <country>China</country></aff>
<aff id="a3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05d5vvz89</institution-id><institution>Department of Oncology, The First Affiliated Hospital of Jinan University</institution></institution-wrap>, <city>Guangzhou</city>, <country>China</country></aff>
<aff id="a4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02xe5ns62</institution-id><institution>MOE Key Laboratory of Tumor Molecular Biology and Key Laboratory of Functional Protein Research of Guangdong Higher Education Institutes, Institute of Life and Health Engineering, Jinan University</institution></institution-wrap>, <city>Guangzhou</city>, <country>China</country></aff>
</contrib-group>
<contrib-group content-type="section">
<contrib contrib-type="editor">
<name>
<surname>Wei</surname>
<given-names>Jia</given-names>
</name>
<role>Reviewing Editor</role>
<aff>
<institution-wrap>
<institution>Department of Oncology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.</institution>
</institution-wrap>
<city>Nanjing</city>
<country>China</country>
</aff>
</contrib>
<contrib contrib-type="senior_editor">
<name>
<surname>Ng</surname>
<given-names>Tony</given-names>
</name>
<role>Senior Editor</role>
<aff>
<institution-wrap>
<institution>King's College London</institution>
</institution-wrap>
<city>London</city>
<country>United Kingdom</country>
</aff>
</contrib>
</contrib-group>
<author-notes>
<fn id="n1" fn-type="equal"><label>*</label><p>These authors contributed equally</p></fn>
<fn fn-type="coi-statement"><p>Competing interest statement: The authors have declared no competing interest.</p></fn>
<fn fn-type="financial-disclosure"><p>Funding Statement: This study was funded by the Clinical Frontier Technology Program of the First Affiliated Hospital of Jinan University (No. JNU1AF-CFTP-2022-a01223), the National Natural Science Foundation of China (82204436), Natural Science Foundation of Guangdong Province (2024A1515030010, 2022A1515011695), Science and Technology Projects in Guangzhou (2024A03J0825).</p></fn>
</author-notes>
<pub-date date-type="original-publication" iso-8601-date="2025-01-21">
<day>21</day>
<month>01</month>
<year>2025</year>
</pub-date>
<volume>14</volume>
<elocation-id>RP103559</elocation-id>
<history>
<date date-type="sent-for-review" iso-8601-date="2024-10-09">
<day>09</day>
<month>10</month>
<year>2024</year>
</date>
</history>
<pub-history>
<event>
<event-desc>Preprint posted</event-desc>
<date date-type="preprint" iso-8601-date="2024-10-13">
<day>13</day>
<month>10</month>
<year>2024</year>
</date>
<self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.10.11.24315215"/>
</event>
</pub-history>
<permissions>
<copyright-statement>© 2025, Zhang et al</copyright-statement>
<copyright-year>2025</copyright-year>
<copyright-holder>Zhang et al</copyright-holder>
<ali:free_to_read/>
<license xlink:href="https://creativecommons.org/licenses/by/4.0/">
<ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="elife-preprint-103559-v1.pdf"/>
<related-object content-type="pre-results" source-id="ChiCTR" source-id-type="registry-name" source-type="clinical-trials-registry" document-id="ChiCTR2200066117" document-id-type="clinical-trial-number" xlink:href="https://www.chictr.org.cn/showprojEN.html?proj=124946">ChiCTR2200066117</related-object>
<abstract>
<title>Abstract</title>
<p>An immunosuppressive tumor microenvironment limits the efficacy of immunotherapy, thus patients with MSS and pMMR mCRC often face great challenges.In this phase II trial, patients received Gamma Knife SBRT combined with Tislelizumab. P Biomarker analysis was performed pre- and post-treatment. From November 2022 to July 2024, 13 of 20 patients achieved PR, 6 achieved SD. mPFS was 10.7 months (95% CI, 6.4-15.0). With no grade 4 events noted, common adverse events included nausea (65%), anemia (55%), and fatigue (45%). For patients who had not responded to first and second-line therapies, the combo of Gamma Knife SBRT and tislelizumab showed high efficacy and reasonable safety. Significant post-radiotherapy improvements in the tumor’s immunosuppressive microenvironment. These results imply that patients with pMMR/MSS/MSI-L mCRC who were unresponsive to the first and second-line chemotherapy, Gamma Knife SBRT with tislelizumab provides a safe and powerful later-line treatment alternative.</p>
</abstract>
<abstract abstract-type="teaser">
<title>Statement of significance</title>
<p>This study offers a safe and powerful option for pMMR/MSS/MSI-L mCRC patients fail to first and second-line chemotherapy. And discover Gamma Knife SBRT contributed to potentially converting the suppressive “cold” tumor immune microenvironment into an activated “hot” microenvironment conducive to immunotherapy efficacy in pMMR CRC.</p>
</abstract>
<kwd-group kwd-group-type="author">
<title>Keywords</title>
<kwd>Gamma Knife Stereotactic body radiation therapy</kwd>
<kwd>mismatch repair-proficient</kwd>
<kwd>tislelizumab</kwd>
<kwd>Metastatic colorectal cancer</kwd>
<kwd>Immune checkpoint inhibitors</kwd>
<kwd>PD-L1</kwd>
</kwd-group>

<custom-meta-group>
<custom-meta specific-use="meta-only">
<meta-name>publishing-route</meta-name>
<meta-value>prc</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>

</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Colorectal cancer continues to represent a significant threat to life. As reported in the 2020 Global Cancer Statistics, colorectal cancer accounts for 10% of all cancer cases, ranking third in incidence, while its mortality rate is 9.4%, second only to lung cancer (<xref ref-type="bibr" rid="c1">1</xref>,<xref ref-type="bibr" rid="c2">2</xref>). Especially, 20% of newly diagnosed colorectal cancer patients present show metastases, and 40% have recurrence and metastases after local treatment (<xref ref-type="bibr" rid="c3">3</xref>). The FOLFOX/FOLFIRI chemotherapy regimen, which comprises oxaliplatin, 5-fluorouracil, and irinotecan is the mainstay of clinical treatment for metastatic colorectal cancer (mCRC). For patients harboring wild-type RAS and BRAF, the addition of the epidermal growth factor receptor (EGFR) inhibitor cetuximab is recommended(<xref ref-type="bibr" rid="c4">4</xref>,<xref ref-type="bibr" rid="c5">5</xref>). For patients with RAS mutations, the anti-angiogenic agent bevacizumab is advised. Nevertheless, RAS-mutant patients exhibit poorer prognoses and shorter survival times compared to their wild-type counterparts (<xref ref-type="bibr" rid="c6">6</xref>,<xref ref-type="bibr" rid="c7">7</xref>). The efficacy of chemotherapy in combination with targeted therapy remains suboptimal (<xref ref-type="bibr" rid="c7">7</xref>).</p>
<p>The development of immune checkpoint inhibitors (ICIs) transforms cancer immunotherapy (<xref ref-type="bibr" rid="c8">8</xref>). Particularly CRCs with mismatch repair deficiency (dMMR) and high microsatellite instability (MSI-H) show a strong response to ICIs (<xref ref-type="bibr" rid="c9">9</xref>). But most CRC cases are either microsatellite-stable/low microsatellite instability (MSS/MSI-L) or mismatch repair-profile (pMMR), which reduces the efficacy of immunotherapy in a significant number of mCRC patients (<xref ref-type="bibr" rid="c9">9</xref>). Chemotherapeutic agents can cause immunogenic cell death in tumors, thus coordinating with ICIs improves anti-tumor efficacy (<xref ref-type="bibr" rid="c10">10</xref>). Additionally, anti-angiogenic therapies targeting VEGFR facilitate the normalization of tumor vasculature and promote immune cell infiltration, subsequently amplifying immune-mediated tumor eradication (<xref ref-type="bibr" rid="c11">11</xref>). Clinical studies, however, have revealed that t combining mFOLFOX6 or other chemotherapy regimens with anti-VEGF, anti-EGFR, and ICIs does not produce better clinical outcomes in mCRC (<xref ref-type="bibr" rid="c12">12</xref>,<xref ref-type="bibr" rid="c13">13</xref>). Consequently, identifying alternative strategies to augment the efficacy of immunotherapy remains a pivotal objective in the field of cancer immunotherapy in pMMR/MSS/MSI-L mCRC.</p>
<p>Stereotactic body radiation therapy (SBRT), effectively targets and eradicates tumor cells with high-dose radiation (<xref ref-type="bibr" rid="c14">14</xref>). Although traditional radiotherapy is sometimes linked with immunosuppressive effects (<xref ref-type="bibr" rid="c15">15</xref>), SBRT’s exact targeting can expose tumor neoantigens, mobilize and activate immune cells, increase their infiltration into the tumor, and improve the tumor immune microenvironment (<xref ref-type="bibr" rid="c16">16</xref>,<xref ref-type="bibr" rid="c17">17</xref>). The Gamma Knife is a principal modality in SBRT, employing gamma rays generated by cobalt-60 to deliver a single, high-dose focused irradiation to the target lesion. The Gamma Knife provides several benefits over conventional radiotherapy, including hiexact stereotactic targeting, increased delivery dose to the lesion, prevention of accelerated repopulation of tumor cells, and better local control rates of tumors(<xref ref-type="bibr" rid="c18">18</xref>). Our team firstly observed a case with pMMR-type mCRC who exhibited local recurrence and distant metastasis following first-line and second-line chemotherapy combined with targeted therapy(<xref ref-type="bibr" rid="c19">19</xref>). After undergoing gamma knife SBRT followed by tislelizumab treatment, intrahepatic metastatic lesions were reduced and stabilized, the patient showed a partial response (PR) with notable reduction of recurrent lesions in the rectal wall and stabilization of intrahepatic metastases, so extending the progression-free survival (PFS) exceeded beyond 3 months (<xref ref-type="bibr" rid="c19">19</xref>). These findings suggest that Gamma Knife SBRT might improve ICBs sensitivity in mCRC.</p>
<p>The results of a phase II clinical trial assessing the combination of Gamma Knife SBRT combined with tislelizumab as a later-line therapy in patients with pMMR/MSS/MSI-L mCRC are presented in this report together with safety and efficacy. NanoString assay for transcriptome analysis was employed to elucidate changes in the tumor immune microenvironment during the combined treatment, offering insights into the therapeutic potential and mechanistic underpinnings of this integrated approach.</p>
</sec>
<sec id="s2">
<title>Results</title>
<sec id="s2a">
<title>Patients</title>
<p>In this clinical trial, twenty patients with pMMR/MSS/MSI-L tumors refractory to first or second-line treatment were enrolled. The cohort comprised 15 males and 5 females, with ages ranging from 47 to 77 years. Predominantly, the primary tumors were located in the left colon and rectum (17/20, 85%), with the liver being the most common site of metastasis, followed by the lung (3/20) (<xref rid="tbl1" ref-type="table">Table 1</xref>). Flowchart of therapeutic regimen and flow diagram of enrolled participants in the study were shown in <xref rid="fig1" ref-type="fig">Figure 1A</xref> and <xref rid="fig1" ref-type="fig">Figure 1B</xref>.</p>
<fig id="fig1" position="float" orientation="portrait" fig-type="figure">
<label>Figure 1.</label>
<caption><title>Clinical trial flow chart.</title>
<p><bold>A)</bold> Flowchart of therapeutic regimen. <bold>B)</bold> Flow diagram of participants in the study.</p></caption>
<graphic xlink:href="24315215v1_fig1.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<p>Molecular profiling revealed RAS mutations in 11 patients (55%), with 5 exhibiting KRAS mutations and 6 presenting NRAS mutations. PD-L1 expression was assessed in 18 patients, 12 (60%) patients had combined positive score (CPS ) ≤ 1. Tumor mutation burden (TMB) data were available for 8 patients, with a median TMB of 4.62 mutations/Mb (IQR 3.08-8.97). Notably, only one patient exhibited a TMB &gt; 10 mutations/Mb (<xref rid="tbl1" ref-type="table">Table 1</xref>).</p>
<table-wrap id="tbl1" orientation="portrait" position="float">
<label>Table 1:</label>
<caption><title>Baseline demographic and clinical characteristics.</title></caption>
<graphic xlink:href="24315215v1_tbl1.tif" mime-subtype="tiff" mimetype="image"/>
<graphic xlink:href="24315215v1_tbl1a.tif" mime-subtype="tiff" mimetype="image"/>
</table-wrap>
</sec>
<sec id="s2b">
<title>Efficacy</title>
<p>In our cohort of 20 patients meeting inclusion criteria, 13 (65%) achieved a partial response (PR), and 6 (35%) maintained stable disease (SD), resulting in a robust disease control rate (DCR) of 95% (<xref rid="tbl2" ref-type="table">Table 2</xref>). Patients with liver metastases achieved 92.9% DCR, and patients with metastases in non-liver locations notably achieved a remarkable 100% DCR, only 1 patient with liver metastases experienced disease progression (PD) (<xref rid="fig2" ref-type="fig">Figure 2A</xref>), As of the data cutoff date, 7 patients remained on maintenance treatment, and 1 patient underwent surgery due to disease progression (<xref rid="fig2" ref-type="fig">Figure 2A</xref>). Remarkably, 3 patients refractory to first-line treatment responded to SBRT combined with tislelizumab, achieving rapid regression to NED status, with durations ranging from 6 to 18 months before progression. Encouragingly, 1 patient remains in a state of NED, under ongoing monitoring (<xref rid="fig2" ref-type="fig">Figure 2A</xref>).</p>
<table-wrap id="tbl2" orientation="portrait" position="float">
<label>Table 2:</label>
<caption><title>Efficacy outcomes.</title></caption>
<graphic xlink:href="24315215v1_tbl2.tif" mime-subtype="tiff" mimetype="image"/>
<graphic xlink:href="24315215v1_tbl2a.tif" mime-subtype="tiff" mimetype="image"/>
</table-wrap>
<fig id="fig2" position="float" orientation="portrait" fig-type="figure">
<label>Figure 2.</label>
<caption><title>Clinical trial results.</title>
<p><bold>A)</bold> Swimmer plots of patients. <bold>B)</bold> Kaplan–Meier curves of OS for the per-protocol set (N = 20). <bold>C)</bold> Kaplan–Meier curves of PFS for the per-protocol set (N = 20). <bold>D)</bold> Kaplan–Meier curves of PFS for didn’t receive immunotherapy set (control group) (N= 23) and per-protocol set (test group) (N=20). <bold>E)</bold> Radiological response from patient. <bold>F)</bold> Waterfall plot of best percent change from baseline in patient target lesion (N= 20). <bold>G)</bold> Waterfall plot of best percent change from baseline in patient off-target lesion (N= 12).</p></caption>
<graphic xlink:href="24315215v1_fig2.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<p>Most patients exhibited favorable survival outcomes throughout the treatment (<xref rid="fig2" ref-type="fig">Figure 2B</xref>), and median progression-free survival (PFS) was 10.7 months (95% CI, 6.4, 15.0) (<xref rid="fig2" ref-type="fig">Figure 2C</xref>). Additionally, a comparative survival analysis included 23 patients who underwent first and second-line treatment and Gamma Knife SBRT without immunotherapy, revealing a median PFS of 6.7 months (95% CI, 5.6, 7.0), this data shown Gamma Knife SBRT combined with tislelizumab as later-line treatment prolong PFS in mCRC (Log-rank test = 5.638, P = 0.0176) (<xref rid="fig2" ref-type="fig">Figure 2D</xref>). These findings suggest Gamma Knife SBRT combined with tislelizumab can effectively inhibiting mCRC progression.</p>
<p>In light of the abscopal effect of radiotherapy, we extended our observations beyond the lesions directly targeted by stereotactic radiotherapy to include non-irradiated lesions. Imaging examinations revealed significant tumor regression in both the irradiated target lesions (<xref rid="fig2" ref-type="fig">Figure 2E</xref><bold>, F</bold>) and the non-irradiated lesions (<xref rid="fig2" ref-type="fig">Figure 2E</xref><bold>, G</bold>) following Gamma Knife SBRT combined with tislelizumab. These findings suggest that SBRT not only impacts the irradiated lesions but also sensitize distant metastatic sites for ICBs through the abscopal effect, thereby enhancing the systemic antitumor response when combined with immunotherapy.</p>
</sec>
<sec id="s2c">
<title>Safety</title>
<p>All 20 enrolled patients received the assigned treatment regimen, with safety assessments conducted every three treatment cycles. Treatment-related adverse events (TRAEs) and immune-related adverse events are summarized in <xref rid="tbl3" ref-type="table">Table 3</xref>. Predominantly, patients experienced mild to moderate adverse events, with the most common being nausea (65%), anemia (55%), electrolyte disturbances (55%), fatigue (45%), and anorexia (35%). Notably, only two patients experienced grade 3 events of increased blood bilirubin, while no grade 4 adverse events were reported throughout the study period.</p>
<table-wrap id="tbl3" orientation="portrait" position="float">
<label>Table 3:</label>
<caption><title>Treatment-emergent adverse events (TEAEs) since the initiation of protocol-specified treatment</title></caption>
<graphic xlink:href="24315215v1_tbl3.tif" mime-subtype="tiff" mimetype="image"/>
</table-wrap>
</sec>
<sec id="s2d">
<title>Identification of differentially expressed genes between responder and non-response groups</title>
<p>To elucidate the impact of the tumor immune microenvironment on combination therapy outcomes, we employed NanoString assay for transcriptome analysis of tumor samples obtained from 16 enrolled patients before and after treatment, totaling 32 samples (<xref rid="fig3" ref-type="fig">Figure 3A</xref>). Patients were stratified into r responder (PR) and non-responder (non-PR) groups based on treatment outcomes. Gene expression differential analysis between pre- and post-treatment samples within each group identified significant alterations, detailed in the <bold>Supplementary Data</bold> and illustrated in <xref rid="fig3" ref-type="fig">Figure 3B</xref>.</p>
<fig id="fig3" position="float" orientation="portrait" fig-type="figure">
<label>Figure 3.</label>
<caption><title>Differential expressed genes analysis.</title>
<p><bold>A)</bold> Specimens collection flowchart. <bold>B)</bold> Transcriptome analysis on differential expression genes before and after treatment between responders (PR) (n = 9) and non-responders (Non-PR) (n = 7), DESeq2 was provided to perform differential expression testing. <bold>C)</bold> The abundance of predefined 12 immune cells composition before and after treatment between responders (PR) (n = 9) and non-responders (Non-PR) (n = 7), Wilcoxon test was used to determine the statistical significance between subgroups. <bold>D)</bold> Radiological response from patient. <bold>E)</bold> Representative CD8 &amp; PD-L1 IHC staining of before and after treatment specimens of patient.</p></caption>
<graphic xlink:href="24315215v1_fig3.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<p>Our findings highlighted notable up-regulation of key genes involved in antigen presentation (CD40, TNFSF18, TNFSF4), immune checkpoint modulation (PDCD1LG2, CD274, IDO1, VTCN1), and T cell activation pathways (TNFRSF9, CD28, ICOS, CD40LG, CD2, GZMK, ENTPD1, ITGAE) in the responder group. Additionally, a diverse array of chemokine family genes (IL2, IL4, IL17A, CCR2, CCL22) showed enhanced expression in PR group (<xref rid="fig3" ref-type="fig">Figure 3B</xref>). Furthermore, immune cell abundance analysis based on 11 predefined immune cell types revealed significantly elevated levels in the PR group compared to non-PR. included T cells, B cells, mast cells, macrophages, Dendritic Cell (DC), Cytotoxic cells, NK CD56 cell, CD8 T cell, CD45 cell, Th1 cells and NK cell (<xref rid="fig3" ref-type="fig">Figure 3C</xref>). This heightened immune activation in responders encompassed robust antigen presentation, T cell activation, and co-stimulation processes crucial for effective immune-mediated tumor control.</p>
<p>Following the combination of stereotactic radiotherapy and immunotherapy, a striking reduction in liver metastasis target lesions was observed in two patients compared to baseline To elucidate these findings, we conducted CD8 and PD-L1 immunohistochemical staining on liver metastasis biopsy specimens from one patient pre- and post-treatment (<xref rid="fig3" ref-type="fig">Fig 3D-E</xref>). The analysis revealed increased infiltration of T cells and improved immune microenvironment following treatment, aligning with our prior analytical findings.</p>
</sec>
<sec id="s2e">
<title>Additional immune signatures analysis in predicting tumor response</title>
<p>We conducted gene expression analysis based on 12 predefined gene sets associated with immunotherapy and prognosis (<xref rid="fig4" ref-type="fig">Figure 4A</xref>). Notably, samples from the responder group exhibited higher expression of immune activation related genes compared to the non-responder group, include effector T cells (T-eff), T cell-Inflamed, IFN-γ, cytotoxic, Cytolytic activity score (CYT), chemokines, angiogenesis (AG), APC co-stimulation (APC co-sti), inflammation promoting (Inflam-pro), T cell co-stimulation (T cell co-sti), parainflammation (parainflam) and tumor-infiltrating lymphocytes (TIL) (<xref rid="fig4" ref-type="fig">Figure 4A</xref>).</p>
<fig id="fig4" position="float" orientation="portrait" fig-type="figure">
<label>Figure 4.</label>
<caption><title>Additional immune signatures analysis.</title>
<p><bold>A)</bold> The expression of 12 gene sets previously reported to be associated with response to immunotherapy and prognosis between responders (PR) (n = 18) and non-responders (Non-PR) (n = 14). <bold>BCD)</bold> 11 gene sets of prognostic value were differentially expressed between responders (PR) (n = 18) and non-responders (Non-PR) (n = 14), box plots are indicated in terms of minima, maxima, centre, bounds of box and whiskers (interquartile range value), and percentile in the style of Tukey, Wilcoxon test was used to determine the statistical significance between subgroups.</p></caption>
<graphic xlink:href="24315215v1_fig4.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<p>Further compared the related-signature score, we found the responders had higher APC and T cell co-stimulation signature scores compared with the non-responder group (<xref rid="fig4" ref-type="fig">Figure 4B</xref>). Moreover, the responders had higher T cell-Inflamed, inflammation promoting and parainflammation signature scores compared with the non-responder group (<xref rid="fig4" ref-type="fig">Figure 4C</xref>). Additionally, increased expression of effector T cell, cytotoxicity, IFN-γ production, and cytolytic activity and TIL signature scores compared with the non-responder group (<xref rid="fig4" ref-type="fig">Figure 4D</xref>).</p>
<p>Further functional insights into differential gene expression between responder and non-responder groups were gained through gene ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses. GO analysis highlighted enrichment in cytokine and chemokine receptor activities, alongside increased T cell and leukocyte proliferation and activation levels in responders (<xref ref-type="fig" rid="figs1">Supplementary Fig 1A</xref>). Correspondingly, KEGG analysis underscored enrichment in pathways involving antigen processing and presentation, T cell receptor signaling, chemokine interactions, and cytokine signaling (<xref ref-type="fig" rid="figs1">Supplementary Fig 1B</xref>). Notably, these results indicated responders after combination of Gamma Knife SBRT and tislelizumab treatment will enhancing tumor antigen presentation and T cell mediated immune response in pMMR/MSS/MSI-L mCRC.</p>
</sec>
<sec id="s2f">
<title>Analysis on differential expression genes before and after treatment in the responders</title>
<p>To unravel the mechanisms driving tumor regression in the responder cohort, we conducted comprehensive gene expression analysis before and after treatment, focusing on 7 gene groups known for their potential inhibitory effects on immunotherapy. Post-treatment analysis revealed significant reductions in exhausted T cells, Th2 cells, and Treg cells, indicative of a favorable shift away from a suppressive immune microenvironment (<xref rid="fig5" ref-type="fig">Figure 5A</xref>). Tumor resistance mechanisms, such as fibrosis and angiogenesis, play pivotal roles in limiting therapeutic efficacy(<xref ref-type="bibr" rid="c20">20</xref>,<xref ref-type="bibr" rid="c21">21</xref>). Initially, evaluation of immunotherapy-related gene groups in partial responders versus non-responders highlighted significantly higher angiogenesis scores in the former, albeit with no significantly difference (<xref rid="fig5" ref-type="fig">Figure 5B</xref>). Recognizing potential biases from pooling samples pre- and post-treatment, we conducted separate analyses within the responder group, expanding our gene set to include fibrosis-related genes. The findings underscored substantial inhibition of both angiogenesis and fibrosis within the tumor microenvironment following SBRT, targeted therapy, and immunotherapy (<xref rid="fig5" ref-type="fig">Figure 5C</xref>).</p>
<fig id="fig5" position="float" orientation="portrait" fig-type="figure">
<label>Figure 5.</label>
<caption><title>Comparison of responders before and after treatment</title>
<p><bold>A)</bold> The expression of 7 gene sets previously reported to be associated with response to immunosuppressive between before treatment (n = 9) and after treatment (n = 9) in the responders (PR). <bold>B)</bold> The expression of Angiogenesis sets between responders (PR) (n = 18) and non-responders (Non-PR) (n = 14). <bold>C)</bold> The expression of Angiogenesis &amp; Fibroblasts sets between before treatment (n = 9) and after treatment (n = 9) in the responders. Box plots are indicated in terms of minima, maxima, centre, bounds of box and whiskers (interquartile range value), and percentile in the style of Tukey, Wilcoxon test was used to determine the statistical significance between subgroups.</p></caption>
<graphic xlink:href="24315215v1_fig5.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<p>Further stratified analysis of non-responder samples before and after treatment revealed no significant alterations in the expression levels of immunosuppression-related or angiogenesis/fibrosis-related gene sets (<xref ref-type="fig" rid="figs2">Supplementary Fig 2</xref>). These insights illuminate critical pathways through which combined therapies modulate the immune landscape and enhance treatment responses in pMMR/MSS/MSI-L mCRC.</p>
</sec>
</sec>
<sec id="s3">
<title>Discussion</title>
<p>By successfully reaching its main endpoint, this phase II trial shows that for combined Gamma Knife SBRT with tislelizumab greatly increases progression-free survival (PFS) in pMMR/MSS/MSI-L mCRC, resistant to first and second-line therapies. For this patient population, the combo treatment has shown both safety and tolerability. By overcoming resistance to first treatment plans, our study presents a creative therapy approach for those unresponsive to conventional treatments that offers a suitable therapeutic option improving clinical outcomes.</p>
<p>Among the several cancers including nasopharyngeal carcinoma, esophageal cancer, liver cancer, and lung cancer, Tislelizumab, a new PD-1 inhibitor, has been shown especially therapeutic efficacy. Combining tislelizumab with chemotherapy has essentially extended PFS in patients across these cancers (<xref ref-type="bibr" rid="c22">22</xref>–<xref ref-type="bibr" rid="c25">25</xref>).While immunotherapy has proven beneficial for some patients, metastatic colorectal cancer (mCRC) presents unique challenges. Particularly in patients with MSS/pMMR tumors, which are marked by low immunogenicity and great resistance to immunotherapy, tumor cells in mCRC often evade immune detection and destruction (<xref ref-type="bibr" rid="c26">26</xref>). By directly targeting and destroying tumor cells, Gamma Knife SBRT presents a potential solution by releasing a significant volume of tumor neoantigens, and improving tumor immunogenicity, so optimizing maximizing the efficacy of subsequent immunotherapy(<xref ref-type="bibr" rid="c27">27</xref>). Furthermore demonstrated to extend survival in non-small cell lung cancer (NSCLC) with patients with brain metastases is the combination of Gamma Knife SBRT and immunotherapy (<xref ref-type="bibr" rid="c28">28</xref>). Still underreported, though, is the possibility of Gamma Knife SBRT coupled with ICIs to improve the response in pMMR/MSS/MSI-L CRC.</p>
<p>In our clinical observations, a notable therapeutic effect was achieved in a patient treated with combined SBRT and immunotherapy. We hypothesize that the addition of tislelizumab following SBRT could extend progression-free survival (PFS) compared to either modality alone. Tumor microenvironment post-radiotherapy showed significant changes revealed by sequencing analysis of tumor samples ‘both before and after combined treatment. More precisely, the microenvironment transitioned from an immunosuppressive, angiogenesis- and fibrosis-promoting state to an immune-enhanced, angiogenesis- and fibrosis-attenuated state. Comparatively to non-responders, responders expressed genes linked to antigen presentation, tumor inflammation, and immune-mediated tumor killing more strongly. Further showing the activation of several signaling pathways associated with tumor cell death, including NF-κB, TNF, and JAK-STAT pathways was enrichment analysis. Furthermore, immunotherapy targets such as PD-L1, showed an elevation, which supports the possibility of efficient later immunotherapy. These findings substantiate our hypothesis that patients with MSS-type mCRC resistant to first-line treatment could benefit significantly from the combination of stereotactic radiotherapy and immunotherapy, with enhanced immunogenicity and a more favorable tumor microenvironment facilitating improved therapeutic outcomes.</p>
<p>This trial restrictions even if its outcomes show promise. First of all, our results could be biased as a single-arm study devoid of a control group. Second, the limited sample size and single-center design of the study lower its statistical power hence more robust conclusions depend on bigger studies. Furthermore, even though general survival (OS) was examined, the follow-up duration was insufficient to establish a reliable median OS. To address these limitations, a multi-center, randomized controlled trial with a larger cohort and extended follow-up period is essential. This will provide a more comprehensive evaluation of the efficacy and safety of combining Gamma Knife SBRT and tislelizumab as a later-line therapy in pMMR/MSS/MSI-L mCRC patients.</p>
<p>Ultimately, for patients with pMMR/MSS/MSI-L mCRC who were unresponsive to first-line therapy regimens, the combination of Gamma Knife SBRT with tislelizumab demonstrated a high disease control rate (DCR) and manageable safety profile. Significant post-radiotherapy improvements in the tumor’s suppressive immune microenvironment, reduced fibrosis, normalized tumor vasculature, and activation of the PD-1/PD-L1 checkpoint pathway revealed by biomarker analyses so improving the efficacy of immunotherapy.</p>
</sec>
<sec id="s4">
<title>Methods</title>
<sec id="s4a">
<title>Study design and participants</title>
<p>This single-arm, phase II trial was conducted at the First Affiliated Hospital of Jinan University to assess the antitumor efficacy and safety of a combined regimen consisting of SBRT and tislelizumab in patients with pMMR/MSS/MSI-L-type metastatic colorectal cancer (mCRC). The study is registered with ClinicalTrials.gov (identifier: ChicTR2200011777). Eligible patients, aged 18-75 years, had confirmed metastatic colorectal cancer. MSS and RAS mutation statuses were determined through gene sequencing, while clinical staging was based on imaging examinations and intraoperative findings. A total of 20 patients were enrolled in the study, with all providing written informed consent. Detailed inclusion and exclusion criteria are available in the <bold>Supplementary Materials</bold>.</p>
</sec>
<sec id="s4b">
<title>Procedures</title>
<p>As illustrated in <xref rid="fig1" ref-type="fig">Figure 1A</xref>, eligible patients received SBRT (administered 5-6 times per week, 3-5 Gy per session) combined with tislelizumab (200 mg on day 1) was incorporated into the treatment regimen. Each three-week cycle comprised a maximum of 12 cycles of induction therapy. Patients achieving complete response (CR), partial response (PR), or stable disease (SD) transitioned to tislelizumab maintenance therapy (200 mg on day 1) until documented disease progression, death, unacceptable toxicity, or patient withdrawal of consent. Treatment response was evaluated using CT or MRI after each treatment cycle. Adverse events were systematically monitored and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 5.0).</p>
<p>The study enrolled 20 eligible patients on November 24, 2022 (<xref rid="fig1" ref-type="fig">Figure 1B</xref>). All patients received at least one dose of the prescribed regimen. As of the data cutoff date (July 24, 2024), six patients continued to receive maintenance therapy. The median follow-up duration was 15 months (range: 3.4-20.0 months, IQR: 9.6-18.2 months). Due to disease-related complications, specimens could not be obtained from four patients, resulting in 16 patients being included in the per-protocol set (PPS).</p>
</sec>
<sec id="s4c">
<title>Outcomes</title>
<p>The primary endpoints of the study were objective response rate (ORR) and safety, encompassing adverse events and serious adverse events, assessed according to RECIST version 1.1. Secondary endpoints included disease control rate (DCR) and progression-free survival (PFS). ORR was defined as the proportion of patients who achieved a best objective response of complete response (CR) or partial response (PR) per RECIST criteria (version 1.1). DCR was defined as the proportion of patients who achieved CR, PR, or stable disease (SD) according to RECIST criteria (version 1.1). PFS was defined as the time from enrollment to the first documented disease progression per RECIST version 1.1 or to death from any cause, whichever occurred first.</p>
</sec>
<sec id="s4d">
<title>CD8 &amp; PD-L1 expression level</title>
<p>Tumoral CD8 &amp; PD-L1 expression was measured by immunohistochemistry (IHC) (22C3 pharmDx assays). The sections were scored for staining intensity according to the following scale: 0 (no staining), 1 (weak staining, light yellow), 2 (moderate staining, yellowish brown), and 3 (strong staining, brown), with 0 and 1 considered low expression, and 2 and 3 considered high expression.</p>
<p>The score is divided into 4 levels according to the percentage of positive cells: 0%≤positive cell percentage ≤ 25%, 1 point; 25%&lt;positive cell percentage ≤ 50%, 2 points; 50%&lt;positive cell percentage≤75%, 3 points; 75%&lt;positive cell percentage≤100%, 4 points. IHC score = cell staining intensity score x positive cell percentage score. The PD-L1 combined positive score (CPS) was defined as the number of PD-L1 positive cells (tumor cells, lymphocytes, macrophages) as a proportion of the total number of tumor cells multiplied by 100. Positive PD-L1 expression was considered when the CPS was &gt;1.</p>
</sec>
<sec id="s4e">
<title>Nanostring panel RNA sequencing</title>
<p>Due to disease-related limitations, specimens could not be obtained from four patients, resulting in a cohort of 16 patients for combined analysis. Tumor tissue samples were collected both before treatment (BT) and after treatment (AT). Gene expression of each sample was measured using the NanoString nCounter platform (NanoString Technologies, Seattle, WA). The quantitative transcriptome data were obtained based on the 289-immuno-gene panel, which includes 289 genes related to the tumor, tumor microenvironment, and immune responses in cancer. The samples that passed the quality control (QC), which included Imaging QC, Binding Density QC, Positive Control Linearity QC, and Positive Normalization QC can be processed in further analysis. The raw count data of 289 genes were normalized using the R package NanoStringNorm according to the geometric mean of five housekeeping genes. The log2 transformation was then performed on the normalized data. Differentially expressed genes were identified using the “DEseq2” package, employing criteria of log2|fold change| &gt; 1 and false discovery rate &lt; 0.05. Heatmaps depicting the expression patterns of these differentially expressed genes were generated using the “ComplexHeatmap” package.</p>
</sec>
<sec id="s4f">
<title>Immune cell profile analyses and Additional immune signatures analysis</title>
<p>The determination of immune cell types and gene sets associated with immunotherapy response was informed by established literature sources (<xref ref-type="bibr" rid="c29">29</xref>,<xref ref-type="bibr" rid="c30">30</xref>). We transformed each attribute (immune signature or gene set) value (GSVA score) xi into xi’ by the equation xi’ = (xi − xmin)/(xmax − xmin), where xmin and xmax represent the minimum and maximum of the ssGSEA scores for the gene set across all samples, respectively. The detailed gene signature list can be found in the <bold>Supplementary Table</bold>.</p>
</sec>
<sec id="s4g">
<title>Gene set enrichment and pathway analysis</title>
<p>The Kyoto Encyclopedia of Genes and Genomes (KEGG) / Gene Ontology (GO) enrichment analysis was performed using the Clusterprofiler R package. The list of gene IDs was used as the input file. The Benjamini-Hochberg method was employed to adjust the p-values. The cut-off threshold of p-values was set to 0.05. The enrichment results were visualized by the ggplot2 R package. The enrichment statistic was set to classic.</p>
</sec>
<sec id="s4h">
<title>Statistical analyses</title>
<p>Progression-free survival (PFS) and OS was estimated utilizing the Kaplan-Meier method. Statistical analyses were conducted using R (version 3.6.1). Differences between subgroups in terms of efficacy response were assessed using the nonparametric Wilcoxon rank-sum test (Mann-Whitney U test), while comparisons between pre- and post-treatment samples were analyzed with the Wilcoxon signed-rank test. Confidence intervals (CIs) for response rates were calculated employing the Clopper-Pearson method, with all reported P values being two-sided. A P value &lt; 0.05 was considered statistically significant.</p>
</sec>
</sec>

</body>
<back>
<sec>
<fig id="figs1" position="float" orientation="portrait" fig-type="figure">
<label>Supplementary Figure 1.</label>
<caption><title>GO enrichment and KEGG pathways analysis of differential expression genes.</title>
<p><bold>A)</bold> GO enrichment analysis were performed to identify the biological process, cellular component and molecular function of differential expression genes. <bold>B)</bold> H KEGG enrichment analysis of differential expression genes.</p></caption>
<graphic xlink:href="24315215v1_figs1.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<fig id="figs2" position="float" orientation="portrait" fig-type="figure">
<label>Supplementary Figure 2.</label>
<caption><title>Comparison of non-responders before and after treatment.</title></caption>
<graphic xlink:href="24315215v1_figs2.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
</sec>
<sec id="s5" sec-type="data-availability">
<title>Data availability</title>
<p>The data generated in this study are available within the article and its <bold>Supplementary Data</bold>. Additional data or resources related to this article are available upon reasonable request from the corresponding authors.</p>
</sec>
<ack>
<title>Acknowledgments</title>
<p>This research was supported by the Clinical Frontier Technology Program of the First Affiliated Hospital of Jinan University (No. JNU1AF-CFTP-2022-a01223), the National Natural Science Foundation of China (82204436), Natural Science Foundation of Guangdong Province (2024A1515030010, 2022A1515011695), Science and Technology Projects in Guangzhou (2024A03J0825).</p>
</ack>
<sec id="d1e1161" sec-type="additional-information">
<title>Additional information</title>
<sec id="s6" sec-type="ethics-statement">
<title>Ethics approval and consent to participate</title>
<p>This trail was conducted in accordance with the Declaration of Helsinki after approval by the Institutional Review Board of The First Affiliated Hospital of Jinan University (KY-2022-236). All patients provided written informed consent. The clinical trial identifier was: ChiCTR2200066117.</p>
</sec>
<sec id="s7">
<title>Author Contributions</title>
<p>Y Zhang, H Guan and S Liu: acquisition of data, analysis of experimental data and drafted the manuscript. H Li and Z Bian: Investigation, visualization and methodology. J He, Z Zhao and S Qiu: data curation, software and formal analysis. T Mo, X Zhang and Z Chen: technical expertise inmanuscript editing. H Ding and X Zhao: assay optimization, acquisition, and analysis and interpretation of histology and pathology. L Wang, Y Pan and J Pan: funding acquisition, designed the study and writing-review and editing the draft.</p>
</sec>
</sec>
<sec id="suppd1e1161" sec-type="supplementary-material">
<title>Additional files</title>
<supplementary-material id="d1e1138">
<label>Supplementary Data</label>
<media xlink:href="supplements/315215_file02.xlsx"/>
</supplementary-material>
<supplementary-material id="d1e1145">
<label>Supplementary material</label>
<media xlink:href="supplements/315215_file03.docx"/>
</supplementary-material>
<supplementary-material id="d1e1152">
<label>Supplementary Tables</label>
<media xlink:href="supplements/315215_file04.xlsx"/>
</supplementary-material>
</sec>
<ref-list>
<title>References</title>
<ref id="c1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sung</surname> <given-names>H</given-names></string-name>, <string-name><surname>Ferlay</surname> <given-names>J</given-names></string-name>, <string-name><surname>Siegel</surname> <given-names>RL</given-names></string-name>, <string-name><surname>Laversanne</surname> <given-names>M</given-names></string-name>, <string-name><surname>Soerjomataram</surname> <given-names>I</given-names></string-name>, <string-name><surname>Jemal</surname> <given-names>A</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries</article-title>. <source>CA: a cancer journal for clinicians</source> <year>2021</year>;<volume>71</volume>(<issue>3</issue>):<fpage>209</fpage>–<lpage>49</lpage> doi <pub-id pub-id-type="doi">10.3322/caac.21660</pub-id>.</mixed-citation></ref>
<ref id="c2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Siegel</surname> <given-names>RL</given-names></string-name>, <string-name><surname>Miller</surname> <given-names>KD</given-names></string-name>, <string-name><surname>Goding Sauer</surname> <given-names>A</given-names></string-name>, <string-name><surname>Fedewa</surname> <given-names>SA</given-names></string-name>, <string-name><surname>Butterly</surname> <given-names>LF</given-names></string-name>, <string-name><surname>Anderson</surname> <given-names>JC</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Colorectal cancer statistics, 2020</article-title>. <source>CA: a cancer journal for clinicians</source> <year>2020</year>;<volume>70</volume>(<issue>3</issue>):<fpage>145</fpage>–<lpage>64</lpage> doi <pub-id pub-id-type="doi">10.3322/caac.21601</pub-id>.</mixed-citation></ref>
<ref id="c3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Biller</surname> <given-names>LH</given-names></string-name>, <string-name><surname>Schrag</surname> <given-names>D</given-names></string-name></person-group>. <article-title>Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review</article-title>. <source>Jama</source> <year>2021</year>;<volume>325</volume>(<issue>7</issue>):<fpage>669</fpage>–<lpage>85</lpage> doi <pub-id pub-id-type="doi">10.1001/jama.2021.0106</pub-id>.</mixed-citation></ref>
<ref id="c4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Diagnosis, Treatment Guidelines For Colorectal Cancer Working Group C</collab></person-group>. <article-title>Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for colorectal cancer 2018 (English version)</article-title>. <source>Chinese journal of cancer research = Chung-kuo yen cheng yen chiu</source> <year>2019</year>;<volume>31</volume>(<issue>1</issue>):<fpage>117</fpage>–<lpage>34</lpage> doi <pub-id pub-id-type="doi">10.21147/j.issn.1000-9604.2019.01.07</pub-id>.</mixed-citation></ref>
<ref id="c5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Benson</surname> <given-names>AB</given-names></string-name>, <string-name><surname>Venook</surname> <given-names>AP</given-names></string-name>, <string-name><surname>Al-Hawary</surname> <given-names>MM</given-names></string-name>, <string-name><surname>Arain</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>YJ</given-names></string-name>, <string-name><surname>Ciombor</surname> <given-names>KK</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology</article-title><source>. Journal of the National Comprehensive Cancer Network : JNCCN</source> <year>2021</year>;<volume>19</volume>(<issue>3</issue>):<fpage>329</fpage>–<lpage>59</lpage> doi <pub-id pub-id-type="doi">10.6004/jnccn.2021.0012</pub-id>.</mixed-citation></ref>
<ref id="c6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cox</surname> <given-names>AD</given-names></string-name>, <string-name><surname>Fesik</surname> <given-names>SW</given-names></string-name>, <string-name><surname>Kimmelman</surname> <given-names>AC</given-names></string-name>, <string-name><surname>Luo</surname> <given-names>J</given-names></string-name>, <string-name><surname>Der</surname> <given-names>CJ</given-names></string-name></person-group>. <article-title>Drugging the undruggable RAS: Mission possible?</article-title> <source>Nature reviews Drug discovery</source> <year>2014</year>;<volume>13</volume>(<issue>11</issue>):<fpage>828</fpage>–<lpage>51</lpage> doi <pub-id pub-id-type="doi">10.1038/nrd4389</pub-id>.</mixed-citation></ref>
<ref id="c7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Modest</surname> <given-names>DP</given-names></string-name>, <string-name><surname>Ricard</surname> <given-names>I</given-names></string-name>, <string-name><surname>Heinemann</surname> <given-names>V</given-names></string-name>, <string-name><surname>Hegewisch-Becker</surname> <given-names>S</given-names></string-name>, <string-name><surname>Schmiegel</surname> <given-names>W</given-names></string-name>, <string-name><surname>Porschen</surname> <given-names>R</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group</article-title><source>. Annals of oncology : official journal of the European Society for Medical Oncology</source> <year>2016</year>;<volume>27</volume>(<issue>9</issue>):<fpage>1746</fpage>–<lpage>53</lpage> doi <pub-id pub-id-type="doi">10.1093/annonc/mdw261</pub-id>.</mixed-citation></ref>
<ref id="c8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Asaoka</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Ijichi</surname> <given-names>H</given-names></string-name>, <string-name><surname>Koike</surname> <given-names>K</given-names></string-name></person-group>. <article-title>PD-1 Blockade in Tumors with Mismatch-Repair Deficiency</article-title>. <source>The New England journal of medicine</source> <year>2015</year>;<volume>373</volume>(<issue>20</issue>):<fpage>1979</fpage> doi <pub-id pub-id-type="doi">10.1056/NEJMc1510353</pub-id>.</mixed-citation></ref>
<ref id="c9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ganesh</surname> <given-names>K</given-names></string-name>, <string-name><surname>Stadler</surname> <given-names>ZK</given-names></string-name>, <string-name><surname>Cercek</surname> <given-names>A</given-names></string-name>, <string-name><surname>Mendelsohn</surname> <given-names>RB</given-names></string-name>, <string-name><surname>Shia</surname> <given-names>J</given-names></string-name>, <string-name><surname>Segal</surname> <given-names>NH</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Immunotherapy in colorectal cancer: rationale, challenges and potential</article-title>. <source>Nature reviews Gastroenterology &amp; hepatology</source> <year>2019</year>;<volume>16</volume>(<issue>6</issue>):<fpage>361</fpage>–<lpage>75</lpage> doi <pub-id pub-id-type="doi">10.1038/s41575-019-0126-x</pub-id>.</mixed-citation></ref>
<ref id="c10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yi</surname> <given-names>M</given-names></string-name>, <string-name><surname>Zheng</surname> <given-names>X</given-names></string-name>, <string-name><surname>Niu</surname> <given-names>M</given-names></string-name>, <string-name><surname>Zhu</surname> <given-names>S</given-names></string-name>, <string-name><surname>Ge</surname> <given-names>H</given-names></string-name>, <string-name><surname>Wu</surname> <given-names>K</given-names></string-name></person-group>. <article-title>Combination strategies with PD-1/PD-L1 blockade: current advances and future directions</article-title>. <source>Molecular cancer</source> <year>2022</year>;<volume>21</volume>(<issue>1</issue>):<fpage>28</fpage> doi <pub-id pub-id-type="doi">10.1186/s12943-021-01489-2</pub-id>.</mixed-citation></ref>
<ref id="c11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Limagne</surname> <given-names>E</given-names></string-name>, <string-name><surname>Euvrard</surname> <given-names>R</given-names></string-name>, <string-name><surname>Thibaudin</surname> <given-names>M</given-names></string-name>, <string-name><surname>Rébé</surname> <given-names>C</given-names></string-name>, <string-name><surname>Derangère</surname> <given-names>V</given-names></string-name>, <string-name><surname>Chevriaux</surname> <given-names>A</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX-Bevacizumab Drug Treatment Regimen</article-title>. <source>Cancer research</source> <year>2016</year>;<volume>76</volume>(<issue>18</issue>):<fpage>5241</fpage>–<lpage>52</lpage> doi <pub-id pub-id-type="doi">10.1158/0008-5472.Can-15-3164</pub-id>.</mixed-citation></ref>
<ref id="c12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hamid</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Pammer</surname> <given-names>LM</given-names></string-name>, <string-name><surname>Lentner</surname> <given-names>TK</given-names></string-name>, <string-name><surname>Doleschal</surname> <given-names>B</given-names></string-name>, <string-name><surname>Gruber</surname> <given-names>R</given-names></string-name>, <string-name><surname>Kocher</surname> <given-names>F</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Immunotherapy for Microsatellite-Stable Metastatic Colorectal Cancer: Can we close the Gap between Potential and Practice?</article-title> <source>Current oncology reports</source> <year>2024</year> doi <pub-id pub-id-type="doi">10.1007/s11912-024-01583-w</pub-id>.</mixed-citation></ref>
<ref id="c13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Antoniotti</surname> <given-names>C</given-names></string-name>, <string-name><surname>Rossini</surname> <given-names>D</given-names></string-name>, <string-name><surname>Pietrantonio</surname> <given-names>F</given-names></string-name>, <string-name><surname>Catteau</surname> <given-names>A</given-names></string-name>, <string-name><surname>Salvatore</surname> <given-names>L</given-names></string-name>, <string-name><surname>Lonardi</surname> <given-names>S</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial</article-title>. <source>The Lancet Oncology</source> <year>2022</year>;<volume>23</volume>(<issue>7</issue>):<fpage>876</fpage>–<lpage>87</lpage> doi <pub-id pub-id-type="doi">10.1016/s1470-2045(22)00274-1</pub-id>.</mixed-citation></ref>
<ref id="c14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Papiez</surname> <given-names>L</given-names></string-name>, <string-name><surname>Timmerman</surname> <given-names>R</given-names></string-name>, <string-name><surname>DesRosiers</surname> <given-names>C</given-names></string-name>, <string-name><surname>Randall</surname> <given-names>M</given-names></string-name></person-group>. <article-title>Extracranial stereotactic radioablation: physical principles. Acta oncologica (Stockholm</article-title>, <source>Sweden</source>) <year>2003</year>;<volume>42</volume>(<issue>8</issue>):<fpage>882</fpage>–<lpage>94</lpage> doi <pub-id pub-id-type="doi">10.1080/02841860310013490</pub-id>.</mixed-citation></ref>
<ref id="c15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>Mac</given-names> <surname>Manus M</surname></string-name>, <string-name><surname>Lamborn</surname> <given-names>K</given-names></string-name>, <string-name><surname>Khan</surname> <given-names>W</given-names></string-name>, <string-name><surname>Varghese</surname> <given-names>A</given-names></string-name>, <string-name><surname>Graef</surname> <given-names>L</given-names></string-name>, <string-name><surname>Knox</surname> <given-names>S</given-names></string-name></person-group>. <article-title>Radiotherapy-associated neutropenia and thrombocytopenia: analysis of risk factors and development of a predictive model</article-title>. <source>Blood</source> <year>1997</year>;<volume>89</volume>(<issue>7</issue>):<fpage>2303</fpage>–<lpage>10</lpage>.</mixed-citation></ref>
<ref id="c16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Singh</surname> <given-names>AK</given-names></string-name>, <string-name><surname>Winslow</surname> <given-names>TB</given-names></string-name>, <string-name><surname>Kermany</surname> <given-names>MH</given-names></string-name>, <string-name><surname>Goritz</surname> <given-names>V</given-names></string-name>, <string-name><surname>Heit</surname> <given-names>L</given-names></string-name>, <string-name><surname>Miller</surname> <given-names>A</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>A Pilot Study of Stereotactic Body Radiation Therapy Combined with Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma</article-title>. <source>Clinical cancer research : an official journal of the American Association for Cancer Research</source> <year>2017</year>;<volume>23</volume>(<issue>17</issue>):<fpage>5055</fpage>–<lpage>65</lpage> doi <pub-id pub-id-type="doi">10.1158/1078-0432.Ccr-16-2946</pub-id>.</mixed-citation></ref>
<ref id="c17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Choi</surname> <given-names>CW</given-names></string-name>, <string-name><surname>Jeong</surname> <given-names>MH</given-names></string-name>, <string-name><surname>Park</surname> <given-names>YS</given-names></string-name>, <string-name><surname>Son</surname> <given-names>CH</given-names></string-name>, <string-name><surname>Lee</surname> <given-names>HR</given-names></string-name>, <string-name><surname>Koh</surname> <given-names>EK</given-names></string-name></person-group>. <article-title>Combination Treatment of Stereotactic Body Radiation Therapy and Immature Dendritic Cell Vaccination for Augmentation of Local and Systemic Effects</article-title>. <source>Cancer research and treatment</source> <year>2019</year>;<volume>51</volume>(<issue>2</issue>):<fpage>464</fpage>–<lpage>73</lpage> doi <pub-id pub-id-type="doi">10.4143/crt.2018.186</pub-id>.</mixed-citation></ref>
<ref id="c18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Morinaga</surname> <given-names>N</given-names></string-name>, <string-name><surname>Tanaka</surname> <given-names>N</given-names></string-name>, <string-name><surname>Shitara</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Ishizaki</surname> <given-names>M</given-names></string-name>, <string-name><surname>Yoshida</surname> <given-names>T</given-names></string-name>, <string-name><surname>Kouga</surname> <given-names>H</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Ten-Year Survival of a Patient Treated with Stereotactic Gamma Knife Radiosurgery for Brain Metastases from Colon Cancer with Ovarian and Lymph Node Metastases: A Case Report</article-title>. <source>Case reports in gastroenterology</source> <year>2016</year>;<volume>10</volume>(<issue>1</issue>):<fpage>199</fpage>–<lpage>206</lpage> doi <pub-id pub-id-type="doi">10.1159/000445976</pub-id>.</mixed-citation></ref>
<ref id="c19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname> <given-names>S</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Lin</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>P</given-names></string-name>, <string-name><surname>Pan</surname> <given-names>Y</given-names></string-name></person-group>. <article-title>Case report: The MSI-L/p-MMR metastatic rectal cancer patient who failed systemic therapy responds to anti-PD-1 immunotherapy after stereotactic body radiation-therapy</article-title>. <source>Frontiers in immunology</source> <year>2022</year>;<volume>13</volume>:<issue>981527</issue> doi <pub-id pub-id-type="doi">10.3389/fimmu.2022.981527</pub-id>.</mixed-citation></ref>
<ref id="c20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Herzog</surname> <given-names>BH</given-names></string-name>, <string-name><surname>Baer</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Borcherding</surname> <given-names>N</given-names></string-name>, <string-name><surname>Kingston</surname> <given-names>NL</given-names></string-name>, <string-name><surname>Belle</surname> <given-names>JI</given-names></string-name>, <string-name><surname>Knolhoff</surname> <given-names>BL</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Tumor-associated fibrosis impairs immune surveillance and response to immune checkpoint blockade in non-small cell lung cancer</article-title>. <source>Science translational medicine</source> <year>2023</year>;<volume>15</volume>(<issue>699</issue>):<fpage>eadh8005</fpage> doi <pub-id pub-id-type="doi">10.1126/scitranslmed.adh8005</pub-id>.</mixed-citation></ref>
<ref id="c21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kopecka</surname> <given-names>J</given-names></string-name>, <string-name><surname>Salaroglio</surname> <given-names>IC</given-names></string-name>, <string-name><surname>Perez-Ruiz</surname> <given-names>E</given-names></string-name>, <string-name><surname>Sarmento-Ribeiro</surname> <given-names>AB</given-names></string-name>, <string-name><surname>Saponara</surname> <given-names>S</given-names></string-name>, <string-name><surname>De Las Rivas</surname> <given-names>J</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Hypoxia as a driver of resistance to immunotherapy</article-title>. <source>Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy</source> <year>2021</year>;<volume>59</volume>:<issue>100787</issue> doi <pub-id pub-id-type="doi">10.1016/j.drup.2021.100787</pub-id>.</mixed-citation></ref>
<ref id="c22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Pan</surname> <given-names>J</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>H</given-names></string-name>, <string-name><surname>Zhao</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Qu</surname> <given-names>S</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>N</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)</article-title>. <source>Cancer cell</source> <year>2023</year>;<volume>41</volume>(<issue>6</issue>):<fpage>1061</fpage>–<lpage>72.e4</lpage> doi <pub-id pub-id-type="doi">10.1016/j.ccell.2023.04.014</pub-id>.</mixed-citation></ref>
<ref id="c23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname> <given-names>J</given-names></string-name>, <string-name><surname>Lu</surname> <given-names>S</given-names></string-name>, <string-name><surname>Yu</surname> <given-names>X</given-names></string-name>, <string-name><surname>Hu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Sun</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>Z</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial</article-title>. <source>JAMA oncology</source> <year>2021</year>;<volume>7</volume>(<issue>5</issue>):<fpage>709</fpage>–<lpage>17</lpage> doi <pub-id pub-id-type="doi">10.1001/jamaoncol.2021.0366</pub-id>.</mixed-citation></ref>
<ref id="c24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shen</surname> <given-names>L</given-names></string-name>, <string-name><surname>Kato</surname> <given-names>K</given-names></string-name>, <string-name><surname>Kim</surname> <given-names>SB</given-names></string-name>, <string-name><surname>Ajani</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Zhao</surname> <given-names>K</given-names></string-name>, <string-name><surname>He</surname> <given-names>Z</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study</article-title>. <source>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</source> <year>2022</year>;<volume>40</volume>(<issue>26</issue>):<fpage>3065</fpage>–<lpage>76</lpage> doi <pub-id pub-id-type="doi">10.1200/jco.21.01926</pub-id>.</mixed-citation></ref>
<ref id="c25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Qin</surname> <given-names>S</given-names></string-name>, <string-name><surname>Kudo</surname> <given-names>M</given-names></string-name>, <string-name><surname>Meyer</surname> <given-names>T</given-names></string-name>, <string-name><surname>Bai</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Guo</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Meng</surname> <given-names>Z</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial</article-title>. <source>JAMA oncology</source> <year>2023</year>;<volume>9</volume>(<issue>12</issue>):<fpage>1651</fpage>–<lpage>9</lpage> doi <pub-id pub-id-type="doi">10.1001/jamaoncol.2023.4003</pub-id>.</mixed-citation></ref>
<ref id="c26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhao</surname> <given-names>W</given-names></string-name>, <string-name><surname>Jin</surname> <given-names>L</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>P</given-names></string-name>, <string-name><surname>Li</surname> <given-names>D</given-names></string-name>, <string-name><surname>Gao</surname> <given-names>W</given-names></string-name>, <string-name><surname>Dong</surname> <given-names>G</given-names></string-name></person-group>. <article-title>Colorectal cancer immunotherapy-Recent progress and future directions</article-title>. <source>Cancer letters</source> <year>2022</year>;<volume>545</volume>:<issue>215816</issue> doi <pub-id pub-id-type="doi">10.1016/j.canlet.2022.215816</pub-id>.</mixed-citation></ref>
<ref id="c27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kievit</surname> <given-names>H</given-names></string-name>, <string-name><surname>Muntinghe-Wagenaar</surname> <given-names>MB</given-names></string-name>, <string-name><surname>Hijmering-Kappelle</surname> <given-names>LBM</given-names></string-name>, <string-name><surname>Hiddinga</surname> <given-names>BI</given-names></string-name>, <string-name><surname>Ubbels</surname> <given-names>JF</given-names></string-name>, <string-name><surname>Wijsman</surname> <given-names>R</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Safety and tolerability of stereotactic radiotherapy combined with durvalumab with or without tremelimumab in advanced non-small cell lung cancer, the phase I SICI trial. Lung cancer (Amsterdam</article-title>, <source>Netherlands</source>) <year>2023</year>;<volume>178</volume>:<fpage>96</fpage>–<lpage>102</lpage> doi <pub-id pub-id-type="doi">10.1016/j.lungcan.2023.02.004</pub-id>.</mixed-citation></ref>
<ref id="c28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cho</surname> <given-names>A</given-names></string-name>, <string-name><surname>Untersteiner</surname> <given-names>H</given-names></string-name>, <string-name><surname>Hirschmann</surname> <given-names>D</given-names></string-name>, <string-name><surname>Shaltout</surname> <given-names>A</given-names></string-name>, <string-name><surname>Göbl</surname> <given-names>P</given-names></string-name>, <string-name><surname>Dorfer</surname> <given-names>C</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Gamma Knife Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy or Targeted Therapy</article-title>. <source>Cancers</source> <year>2020</year>;<volume>12</volume>(<issue>12</issue>) doi <pub-id pub-id-type="doi">10.3390/cancers12123668</pub-id>.</mixed-citation></ref>
<ref id="c29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>He</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Jiang</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>C</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>X</given-names></string-name></person-group>. <article-title>Classification of triple-negative breast cancers based on Immunogenomic profiling</article-title>. <source>Journal of experimental &amp; clinical cancer research : CR</source> <year>2018</year>;<volume>37</volume>(<issue>1</issue>):<fpage>327</fpage> doi <pub-id pub-id-type="doi">10.1186/s13046-018-1002-1</pub-id>.</mixed-citation></ref>
<ref id="c30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zeng</surname> <given-names>TM</given-names></string-name>, <string-name><surname>Yang</surname> <given-names>G</given-names></string-name>, <string-name><surname>Lou</surname> <given-names>C</given-names></string-name>, <string-name><surname>Wei</surname> <given-names>W</given-names></string-name>, <string-name><surname>Tao</surname> <given-names>CJ</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>XY</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Clinical and biomarker analyses of sintilimab plus gemcitabine and cisplatin as first-line treatment for patients with advanced biliary tract cancer</article-title>. <source>Nature communications</source> <year>2023</year>;<volume>14</volume>(<issue>1</issue>):<fpage>1340</fpage> doi <pub-id pub-id-type="doi">10.1038/s41467-023-37030-w</pub-id>.</mixed-citation></ref>
</ref-list>
</back>
<sub-article id="sa0" article-type="editor-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.103559.1.sa2</article-id>
<title-group>
<article-title>eLife Assessment</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Wei</surname>
<given-names>Jia</given-names>
</name>
<role specific-use="editor">Reviewing Editor</role>
<aff>
<institution-wrap>
<institution>Department of Oncology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.</institution>
</institution-wrap>
<city>Nanjing</city>
<country>China</country>
</aff>
</contrib>
</contrib-group>
<kwd-group kwd-group-type="evidence-strength">
<kwd>Convincing</kwd>
</kwd-group>
<kwd-group kwd-group-type="claim-importance">
<kwd>Valuable</kwd>
</kwd-group>
</front-stub>
<body>
<p>This <bold>valuable</bold> study highlights the potential of combining immunotherapy for pMMR CRC by selecting suitable cases and demonstrating that Gamma Knife SBRT with tislelizumab provides a safe and effective later-line treatment option for patients with pMMR/MSS/MSI-L mCRC unresponsive to standard chemotherapy. The authors employed a robust experimental design and rigorous statistical analyses to ensure the reliability of their findings. Their results offer <bold>convincing</bold> evidence to support the clinical value of this combined therapeutic approach.</p>
</body>
</sub-article>
<sub-article id="sa1" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.103559.1.sa1</article-id>
<title-group>
<article-title>Reviewer #1 (Public review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Summary:</p>
<p>This study presents compelling evidence for a novel treatment approach in a challenging patient population with MSS/pMMR mCRC, where traditional immunotherapy has often fallen short. The combination of SBRT and tislelizumab not only yielded a high disease control rate but also indicated significant improvements in the tumor's immune landscape. The safety profile appears favorable, which is crucial for patients who have already undergone multiple lines of therapy.</p>
<p>Strengths:</p>
<p>The results underscore the potential of leveraging radiation therapy to enhance the effectiveness of immunotherapy, especially in tumor environments previously deemed hostile to immune interventions. Future research should focus on larger cohorts to validate these findings and explore the underlying mechanisms of immune modulation post-treatment.</p>
<p>Weaknesses:</p>
<p>I believe the author's work is commendable and should be considered with some minor modifications:</p>
<p>(1) While the author categorized patients based on the type of RAS mutation and the location of colorectal cancer metastasis, the article does not adequately address how these classifications influence treatment outcomes. Such as whether KRAS or NRAS mutations, as well as the type of metastatic lesions, affect the sensitivity to gamma-ray treatment and lead to varying responses.</p>
<p>(2) In Figure 2, clarification is needed on how the author differentiated between on-target and off-target lesions. I observed that some images depicted both lesion types at the same level, which could lead to confusion.</p>
<p>(3) The author performed only a basic difference analysis. A more comprehensive analysis, including calculations of markers related to treatment efficacy, could offer additional insights for clinical practice.</p>
<p>(4) The transcriptome sequencing analysis provides insights into how stereotactic radiotherapy sensitizes immunotherapy; however, it currently relies on a simple pre- and post-treatment group comparison. It would be beneficial to include additional subgroups to explore more nuanced findings.</p>
<p>(5) The author briefly discusses the effects of changes in tumor fibrosis and angiogenesis on treatment outcomes. Further experiments may be necessary to validate these findings and investigate the underlying mechanisms of immune regulation following treatment.</p>
</body>
</sub-article>
<sub-article id="sa2" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.103559.1.sa0</article-id>
<title-group>
<article-title>Reviewer #2 (Public review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Summary:</p>
<p>This Phase II clinical trial investigates the combination of Gamma Knife Stereotactic Body Radiation Therapy (SBRT) with Tislelizumab for the treatment of metastatic colorectal cancer (mCRC) in patients with proficient mismatch repair (pMMR). The study addresses a critical clinical challenge in the management of pMMR CRC, focusing on the selection of appropriate candidates. The results suggest that the combination of Gamma Knife SBRT and Tislelizumab provides a safe and potent treatment option for patients with pMMR/MSS/MSI-L mCRC who have become refractory to first- and second-line chemotherapy. The study design is rigorous, and the outcomes are promising.</p>
<p>Advantage:</p>
<p>The trial design was meticulously structured, and appropriate statistical methods were employed to rigorously analyze the results. Bioinformatics approaches were utilized to further elucidate alterations in the patient's tumor microenvironment and to explore the underlying factors contributing to the observed differences in treatment efficacy. The conclusions drawn from this trial offer valuable insights for managing advanced colorectal cancer in patients who have not responded to first- and second-line therapies.</p>
<p>Weakness:</p>
<p>(1) Clarity and Structure of the Abstract</p>
<p>
- Results Section: The results section should contain important data, I suggest some important sequencing data should be shown to enhance understanding.</p>
<p>
(2) As the author using the NanoString assay for transcriptome analysis, more detail should be shown such as the version of R, and the bioinformatics analysis methods.</p>
<p>
(3) It is interesting for included patients that PD-L1 increase expression after Gamma Knife Stereotactic Body Radiation Therapy (SBRT) treatment, How to explain it?</p>
<p>
(4) It would be helpful to include a brief discussion of the limitations of the study, such as sample size constraints and their impact on the generalizability of the results. This will give readers a more comprehensive understanding of the findings.</p>
<p>
(5) Language Accuracy: There are a few instances where wording could be more professional or precise.</p>
</body>
</sub-article>
<sub-article id="sa3" article-type="author-comment">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.103559.1.sa3</article-id>
<title-group>
<article-title>Author response:</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Yiran</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Guan</surname>
<given-names>Hanyang</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">http://orcid.org/0009-0002-8853-6151</contrib-id></contrib>
<contrib contrib-type="author">
<name>
<surname>Liu</surname>
<given-names>Shijin</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Haoquan</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bian</surname>
<given-names>Zili</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>He</surname>
<given-names>Jiashuai</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhao</surname>
<given-names>Zhan</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Qiu</surname>
<given-names>Shenghui</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mo</surname>
<given-names>Tianmu</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Xiangwei</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Zuyang</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ding</surname>
<given-names>Hui</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhao</surname>
<given-names>Xiaoxu</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Liang</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pan</surname>
<given-names>Yunlong</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pan</surname>
<given-names>Jinghua</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3741-3397</contrib-id></contrib>
</contrib-group>
</front-stub>
<body>
<p>We would like to express our sincere gratitude to the editor and reviewers for their thoughtful comments and suggestions on our manuscript. Below is our interim response to the reviewers’ public review:</p>
<p><bold>Reviewer 1:</bold></p>
<p>(1) We appreciate the reviewer’s insightful comment on the consideration of RAS mutation type and lesion metastasis site in our study. We will undertake a more comprehensive review of the literature and conduct a detailed analysis to assess how these factors influence treatment efficacy in our cohort.</p>
<p>(2) Regarding the radiotherapy planning process, we will provide further clarification in the revised manuscript. Specifically, we select the target lesion using CT imaging and delineate it by marking the 50% isodose line to define the planning target volume (PTV). In assessing treatment efficacy, we differentiate between target lesions (within the PTV) and off-target lesions (outside the PTV). We will update the figures to include the isodose line display for better clarity.</p>
<p>(3 &amp; 4) We acknowledge the limitations of our study, particularly with respect to the sample size, which may hinder the statistical power required for a comprehensive analysis of treatment effect markers and subgroup variations. Nonetheless, we will continue to refine our analyses in the revised manuscript to provide additional insights and strengthen the conclusions where possible.</p>
<p>(5) During the early stages of our research, our team conducted a series of investigations into the impact of tumor fibrosis and angiogenesis on treatment outcomes. We have accumulated a substantial body of data, and we will summarize these findings in the revised manuscript to provide further context and support for our current study.</p>
<p><bold>Reviewer 2:</bold></p>
<p>(1, 4 &amp; 5) We greatly appreciate the reviewer’s careful reading of the manuscript. We will revise the abstract, methods, and results sections to improve clarity and precision. Additionally, we will refine the overall wording of the manuscript to enhance its scientific rigor and professionalism.</p>
<p>(2) We also appreciate the reviewer’s suggestions regarding the methods and results. These will be incorporated into the revised manuscript, with additional detail in the methods section to clarify our experimental approach and strengthen the discussion of our findings.</p>
<p>(3) This is an intriguing point raised by the reviewer. We agree that the upregulation of PD-L1 expression following SBRT treatment could potentially enhance the efficacy of subsequent immunotherapy. To explore this further, we will conduct a detailed literature review and provide a more in-depth analysis of our data to elucidate the underlying mechanisms.</p>
<p>We trust that the clarifications provided above partially address the reviewers' concerns. We are committed to fully resolving the raised issues through more comprehensive revisions in the subsequent manuscript update.</p>
</body>
</sub-article>
</article>